NCT06422520
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06422520
Title A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors BeiGene
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | AUS

Facility Status City State Zip Country Details
Florida Cancer Specialist Research Institute Lake Nona Orlando Florida 32827-7400 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215-5418 United States Details
Washington University School of Medicine St Louis Missouri 63110-1010 United States Details
The University of Texas Md Anderson Cancer Center Houston Texas 77030-4009 United States Details
Next Oncology San Antonio Texas 78229-6028 United States Details
Westmead Hospital Westmead New South Wales NSW 2145 Australia Details
St Vincents Hospital Melbourne Fitzroy Victoria VIC 3065 Australia Details
The Alfred Hospital Melbourne Victoria VIC 3004 Australia Details
One Clinical Research Nedlands Western Australia WA 6009 Australia Details
Beijing Cancer Hospital Beijing Beijing Municipality 100142 China Details
Hubei Cancer Hospital Wuhan Hubei 430079 China Details
Jilin Cancer Hospital Changchun Jilin 130021 China Details
Liaoning Cancer Hospital and Institute Shenyang Liaoning 110042 China Details
West China Hospital, Sichuan University Chengdu Sichuan 610041 China Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field